Market Overview:
The global orexin receptor type 2 market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of sleep disorders and rising demand for novel therapies for treating these disorders. The global orexin receptor type 2 market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into HTL-6641, MK-8133, lemborexant, OPN-021, YNT-185 and others. On the basis of application, the market is segmented into insomnia disorder treatment (primary insomnia), narcolepsy disorder treatment (primary narcolepsy), sleep apnea syndrome treatment (obstructive sleep apnea), restless leg syndrome treatment (restless leg syndrome) and major depressive disorder treatment (major depressive episode). Geographically speaking North America dominates this space with Europe following closely behind it owing to better reimbursement scenario in these regions as compared to other regions such as Asia Pacific or Latin America.
Product Definition:
The orexin receptor type 2 (OX2) is a G-protein coupled receptor that binds to the neuropeptide orexin. OX2 is expressed in many regions of the brain, including the hypothalamus, where it regulates energy balance and arousal. The importance of OX2 in regulating these processes has been demonstrated by studies that show knockout mice lacking OX2 are obese and exhibit reduced levels of activity.
HTL-6641:
HTL-6641 is a novel, potent and selective orexin receptor modulator (ORM) for the treatment of narcolepsy with cataplexy. It has completed phase 2 clinical trial and is currently in phase 3 clinical trial. The drug has strong scientific support as it works through same mechanism as popular sleep aid, melatonin.
MK-8133:
MK-8133 is a selective ligand for orexin receptor type 2 (OR2). It was developed by Eisai Co. Ltd. and is currently under clinical investigation in the U.S., Japan, Germany, China and South Korea for treatment of sleep apnea and other sleep disorders associated with OR2A/B gene variants.
Application Insights:
The insomnia segment dominated the global market in terms of revenue in 2017. Orexin receptors are known to play a crucial role in the pathophysiology of sleep disorders such as insomnia and narcolepsy. The growing prevalence of these disorders is anticipated to fuel product demand over the forecast period. Moreover, orexin receptors have been proved to be effective against major depressive disorder and other sleep related disorders, which is expected to propel their usage for treatment purposes over the coming years.
Sleep disorders accounted for a significant share owing to increasing awareness about early diagnosis and treatment options available for sleeping problems such as obstructive sleep apnea (OSA), shift work disorder (SWD) among others. In addition, an increase in spending on nocturnal medications has also resulted in increased sales of pharmaceutical companies that manufacture these drugs resulting in high growth rate for this segment during recent years.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of sleep disorders are some factors attributing to its largest share. In addition, growing awareness about orexin receptors is also expected to contribute towards the growth during the forecast period.
Asia Pacific region is anticipated to witness a lucrative CAGR over the forecast period owing to rising disposable income and improving healthcare infrastructure in emerging countries such as China and India. Furthermore, an increase in R&D initiatives by pharmaceutical companies for developing novel drugs targeting OX2Rs will further boost revenue generation during the forecast period (2016-2030). For instance, Sun Pharma & WOCKHARDT are engaged into research collaborations for development of new formulations targeting OX2Rs (Vishnu Bhatnagar et al., 2016).
Growth Factors:
- Increasing prevalence of sleep disorders: The increasing prevalence of sleep disorders is one of the key growth drivers for the orexin receptor type 2 market. According to a study by the Centers for Disease Control and Prevention (CDC), around 50-70 million adults in the U.S. suffer from some form of sleep disorder, which is around 30% of the population. This number is expected to increase in future due to changing lifestyle and growing stress levels. This will create demand for orexin receptor type 2 drugs and boost market growth during forecast period
- Rising awareness about benefits of orexin receptor type 2 drugs: There is growing awareness among people about benefits of orexin receptor type 2 drugs, which is driving demand for these drugs globally. Orexins are neuropeptides that play an important role in regulating wakefulness and arousal state, thereby helping improve overall quality of life in people suffering from sleep disorders or other conditions associated with disturbed wakefulness such as narcolepsy or obesity etcetera .This will help boost market growth during forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Orexin Receptor Type 2 Market Research Report
By Type
HTL-6641, MK-8133, Lemborexant, OPN-021, YNT-185, Others
By Application
Insomnia, Narcolepsy, Sleep Disorders, Major Depressive Disorder
By Companies
Actelion Pharmaceuticals Ltd, Eisai Co Ltd, Evotec AG, Heptares Therapeutics Ltd, Idorsia Ltd, Johnson & Johnson, Merck & Co Inc, OptiNose US Inc, Yangtze River Pharmaceutical Group
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Orexin Receptor Type 2 Market Report Segments:
The global Orexin Receptor Type 2 market is segmented on the basis of:
Types
HTL-6641, MK-8133, Lemborexant, OPN-021, YNT-185, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Insomnia, Narcolepsy, Sleep Disorders, Major Depressive Disorder
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Actelion Pharmaceuticals Ltd
- Eisai Co Ltd
- Evotec AG
- Heptares Therapeutics Ltd
- Idorsia Ltd
- Johnson & Johnson
- Merck & Co Inc
- OptiNose US Inc
- Yangtze River Pharmaceutical Group
Highlights of The Orexin Receptor Type 2 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- HTL-6641
- MK-8133
- Lemborexant
- OPN-021
- YNT-185
- Others
- By Application:
- Insomnia
- Narcolepsy
- Sleep Disorders
- Major Depressive Disorder
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Orexin Receptor Type 2 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Orexin receptor type 2 is a protein that helps control the body's sleep and wake cycles. It is also involved in eating, drinking, and other activities during the night.
Some of the major players in the orexin receptor type 2 market are Actelion Pharmaceuticals Ltd, Eisai Co Ltd, Evotec AG, Heptares Therapeutics Ltd, Idorsia Ltd, Johnson & Johnson, Merck & Co Inc, OptiNose US Inc, Yangtze River Pharmaceutical Group.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Orexin Receptor Type 2 Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Orexin Receptor Type 2 Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Orexin Receptor Type 2 Market - Supply Chain
4.5. Global Orexin Receptor Type 2 Market Forecast
4.5.1. Orexin Receptor Type 2 Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Orexin Receptor Type 2 Market Size (000 Units) and Y-o-Y Growth
4.5.3. Orexin Receptor Type 2 Market Absolute $ Opportunity
5. Global Orexin Receptor Type 2 Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Orexin Receptor Type 2 Market Size and Volume Forecast by Type
5.3.1. HTL-6641
5.3.2. MK-8133
5.3.3. Lemborexant
5.3.4. OPN-021
5.3.5. YNT-185
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Orexin Receptor Type 2 Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Orexin Receptor Type 2 Market Size and Volume Forecast by Application
6.3.1. Insomnia
6.3.2. Narcolepsy
6.3.3. Sleep Disorders
6.3.4. Major Depressive Disorder
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Orexin Receptor Type 2 Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Orexin Receptor Type 2 Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Orexin Receptor Type 2 Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Orexin Receptor Type 2 Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Orexin Receptor Type 2 Demand Share Forecast, 2019-2026
9. North America Orexin Receptor Type 2 Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Orexin Receptor Type 2 Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Orexin Receptor Type 2 Market Size and Volume Forecast by Application
9.4.1. Insomnia
9.4.2. Narcolepsy
9.4.3. Sleep Disorders
9.4.4. Major Depressive Disorder
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Orexin Receptor Type 2 Market Size and Volume Forecast by Type
9.7.1. HTL-6641
9.7.2. MK-8133
9.7.3. Lemborexant
9.7.4. OPN-021
9.7.5. YNT-185
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Orexin Receptor Type 2 Demand Share Forecast, 2019-2026
10. Latin America Orexin Receptor Type 2 Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Orexin Receptor Type 2 Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Orexin Receptor Type 2 Market Size and Volume Forecast by Application
10.4.1. Insomnia
10.4.2. Narcolepsy
10.4.3. Sleep Disorders
10.4.4. Major Depressive Disorder
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Orexin Receptor Type 2 Market Size and Volume Forecast by Type
10.7.1. HTL-6641
10.7.2. MK-8133
10.7.3. Lemborexant
10.7.4. OPN-021
10.7.5. YNT-185
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Orexin Receptor Type 2 Demand Share Forecast, 2019-2026
11. Europe Orexin Receptor Type 2 Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Orexin Receptor Type 2 Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Orexin Receptor Type 2 Market Size and Volume Forecast by Application
11.4.1. Insomnia
11.4.2. Narcolepsy
11.4.3. Sleep Disorders
11.4.4. Major Depressive Disorder
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Orexin Receptor Type 2 Market Size and Volume Forecast by Type
11.7.1. HTL-6641
11.7.2. MK-8133
11.7.3. Lemborexant
11.7.4. OPN-021
11.7.5. YNT-185
11.7.6. Others
1.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Orexin Receptor Type 2 Demand Share, 2019-2026
12. Asia Pacific Orexin Receptor Type 2 Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Orexin Receptor Type 2 Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Orexin Receptor Type 2 Market Size and Volume Forecast by Application
12.4.1. Insomnia
12.4.2. Narcolepsy
12.4.3. Sleep Disorders
12.4.4. Major Depressive Disorder
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Orexin Receptor Type 2 Market Size and Volume Forecast by Type
12.7.1. HTL-6641
12.7.2. MK-8133
12.7.3. Lemborexant
12.7.4. OPN-021
12.7.5. YNT-185
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Orexin Receptor Type 2 Demand Share, 2019-2026
13. Middle East & Africa Orexin Receptor Type 2 Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Orexin Receptor Type 2 Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Orexin Receptor Type 2 Market Size and Volume Forecast by Application
13.4.1. Insomnia
13.4.2. Narcolepsy
13.4.3. Sleep Disorders
13.4.4. Major Depressive Disorder
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Orexin Receptor Type 2 Market Size and Volume Forecast by Type
13.7.1. HTL-6641
13.7.2. MK-8133
13.7.3. Lemborexant
13.7.4. OPN-021
13.7.5. YNT-185
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Orexin Receptor Type 2 Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Orexin Receptor Type 2 Market: Market Share Analysis
14.2. Orexin Receptor Type 2 Distributors and Customers
14.3. Orexin Receptor Type 2 Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Actelion Pharmaceuticals Ltd
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Eisai Co Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Evotec AG
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Heptares Therapeutics Ltd
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Idorsia Ltd
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Johnson & Johnson
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Merck & Co Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. OptiNose US Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Yangtze River Pharmaceutical Group
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
